 Interim results from Tiziana Life Sciences PLC NASDAQ:TLSA, LSE:TILS, FRA:RTRA, OTC:TIZAF revealed the significant progress made by the drug developer in the first half of the year. In the six-month period to 30 June, the group was able to provide the first early demonstration that its monoclonal antibody mAB treatment, Foralumab, could be administered nasally using the local and lymphatic immune systems directly. 